This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk adults aged 50-59 this week. Read more here.

ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease: New York Saturday, April 19, 2025, 10:00 Hrs [ ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

“We are proud that ABRYSVO has the broadest indication among RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect ...